Dr. Kai Guo | Next-Generation Sequencing | Best Researcher Award

University of Michigan | United States

Author Profile

Scopus

Orcid ID

Google Scholar

BIOGRAPHY OF DR. KAI GUO, PH.D. - PIONEER IN COMPUTATIONAL BIOLOGY & OMICS ANALYSIS

EARLY ACADEMIC PURSUITS

DR. KAI GUO began his academic journey in the field of biotechnology at Huazhong Agricultural University, Wuhan, China. He obtained:

• B.S. in Biotechnology (2005–2008)

• M.S. in Biochemistry and Molecular Biology (2008–2010)

• Ph.D. in Biochemistry and Molecular Biology (2010–2015)

His foundational training equipped him with strong skills in molecular biology and computational techniques, paving the way for a highly interdisciplinary career.

PROFESSIONAL ENDEAVORS

Dr. Guo has held numerous academic and research positions across prestigious institutions:

• Research Assistant Professor, Department of Neurology, University of Michigan (2022–Present)

• Adjunct Professor, Chongqing Medical University (2022–Present)

• Visiting Scholar, University of North Dakota (2020–Present)

• Post-doctoral Research Fellow, University of Michigan (2020–2022)

• Post-doctoral Research Fellow, University of North Dakota (2016–2020)

• Visiting Scholar, University of Michigan (2018–2019)

• Bioinformatics Engineer, Katie Wuhan Engineering Technology Research Institute (2013–2014)

His global experience has bridged bioinformatics, neurology, and genomics, establishing him as a versatile and impactful researcher.

CONTRIBUTIONS AND RESEARCH FOCUS ON NEXT-GENERATION SEQUENCING

Dr. Guo’s research centers on multi-omics data analysis and advanced computational biology techniques, with a broad portfolio including:

• High-throughput omics data analysis

• Epigenetics

• Transcriptomic Analysis

• Genome Assembly

• Molecular Evolution

• Systems Biology

• Machine Learning & Deep Learning

He applies these tools to decipher complex biological mechanisms, particularly in neurological contexts.

IMPACT AND INFLUENCE

Dr. Guo is an active member of key scientific organizations:

• Sigma Xi, Full Member (from Feb. 2025)

• International Society for Computational Biology, Member (2018–2025)

His work has contributed significantly to translational biomedical research, especially through epigenomic analysis and next-gen sequencing methodologies.

TEACHING AND KNOWLEDGE SHARING

Dr. Guo has made substantial contributions to academic training through teaching and workshops:

• Taught Biochemistry, Perl, R, and Python programming

• Led workshops in NGS (Next Generation Sequencing) and Single Cell Sequencing Technology

• Trained graduate students in both in-person and online formats across institutions in China and the U.S.

His commitment to education has empowered the next generation of computational biologists.

ACADEMIC CITATIONS

Dr. Guo maintains a visible scholarly presence with a Google Scholar profile showcasing his:

• Peer-reviewed publications

• Contributions marked by equal contribution and $(co-)corresponding authorship

• Active citation metrics reflecting his research visibility and impact

Google Scholar Profile

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Guo is positioned at the forefront of interdisciplinary bioscience, contributing not only through publications but also through global collaborations and institutional development. His anticipated future work includes:

• Further integration of AI with omics research

• Expanding neurological disease modeling through deep learning

• Advancing precision medicine using system biology frameworks

HIGHLIGHTS AND ACHIEVEMENTS

• Research Assistant Professor at a leading U.S. medical university

• Dual appointments in the U.S. and China

• Strong publication record and active participation in cutting-edge biological research

• Mentorship and instruction in both developed and developing academic environments

CONCLUSION

Dr. Kai Guo stands as a rising figure in the integration of bioinformatics, machine learning, and systems biology, with a career marked by innovation, mentorship, and cross-disciplinary impact. His contributions continue to shape how we understand and treat complex diseases through data-driven discovery.

NOTABLE PUBLICATIONS

"Mitochondrial Oxidative Stress Regulates FOXP3+ T-Cell Activity and CD4-Mediated Inflammation in Older Adults with Frailty" 

• Authors: J.S., Gill, Jappreet Singh , B., Bansal, Benu , K., Guo, Kai , N., Khan, Nadeem , R.K., Mathur, Ram Kumar
• Journal: International Journal of Molecular Sciences
• Year: 2024

"Metabolic stress and age drive inflammation and cognitive decline in mice and humans" 

• Authors: S.E., Elzinga, Sarah E. , K., Guo, Kai , A., Turfah, Ali , J., Hur, Junguk , E.L., Feldman, Eva L.
• Journal: Alzheimer's and Dementia
• Year: 205

"Longitudinal Metabolomics in Amyotrophic Lateral Sclerosis Implicates Impaired Lipid Metabolism" 

• Authors: K., Guo, Kai , M.G., Savelieff, Masha Georges , D., Jang, Dae-gyu , S.A., Goutman, Stephen A. , E.L., Feldman, Eva L.
• Journal: Annals of Neurology
• Year: 2025

"Integrative Multi-Omics and Routine Blood Analysis Using Deep Learning: Cost-Effective Early Prediction of Chronic Disease Risks" 

• Authors: Z., Dong, Zhibing , P., Li, Pei , Y., Jiang, Yi , E., Zhu, En , K., He, Kunlun
• Journal: Advanced Science
• Year: 2024

"Transcriptomic profiling of sciatic nerves and dorsal root ganglia reveals site-specific effects of prediabetic neuropathy" 

• Authors: Translational Research
• Journal: Journal of Medical Virology
• Year: 2024

Prof. Zheng Lili | HPV infection | Best Researcher Award

Liaocheng Peoples‘ Hospital | China

Author Profile

Scopus

BIOGRAPHY OF LILI ZHENG: ADVANCING PUBLIC HEALTH THROUGH INFECTIOUS DISEASE RESEARCH

EARLY ACADEMIC PURSUITS

LILI ZHENG embarked on her academic journey with a profound interest in medical science and public health. She earned her Bachelor’s degree from Guilin Medical College (2002.9–2006.7), where she laid the foundational knowledge in medicine. With a growing curiosity in epidemiology and infectious diseases, she further pursued a Master’s degree at the University of South China (2006.9–2009.7), deepening her specialization in infectious diseases and host genetics. This period shaped her scientific rigor and commitment to understanding complex biological interactions, particularly those related to human papillomavirus (HPV) infections.

PROFESSIONAL ENDEAVORS

Since 2009, Lili Zheng has been an integral part of Liaocheng People’s Hospital, where she serves in the Central Library Department. Her professional role goes beyond traditional librarianship, as she combines her scientific expertise with academic support services to foster a research-driven medical environment. Her affiliation reflects a unique blend of academic support and research advancement in a clinical setting.

CONTRIBUTIONS AND RESEARCH FOCUS ON HPV INFECTION

Lili Zheng's research is characterized by an interdisciplinary focus that bridges epidemiology, microbiology, public health, and molecular genetics. Her primary research themes include:

• Epidemiological Study of Infectious Diseases

• HPV Infection and Related Diseases

• Diagnosis and Treatment of Cervical Cancer

• Public Health and Preventive Medicine

• Microbiology and Human Health

Her scholarly work emphasizes HPV-related infections, with a particular focus on understanding the mechanisms of disease progression and effective prevention strategies for cervical cancer, a leading cause of morbidity among women globally. She actively contributes to scientific dialogues on infectious disease control, demonstrating a strong commitment to improving community health outcomes.

IMPACT AND INFLUENCE

Lili Zheng's impact is multidimensional. Academically, her research adds valuable knowledge to the field of infectious diseases and host genetics, especially concerning HPV epidemiology in China. Clinically, her insights inform better diagnostic and treatment practices in cervical cancer management. Her institutional presence at Liaocheng People’s Hospital supports a culture of evidence-based practice and continuous learning. Through academic dissemination and mentorship, she has influenced both researchers and healthcare practitioners.

ACADEMIC CITES

Lili Zheng is indexed on ORCID ID, which reflects her growing academic visibility. As a contributor to HPV-related research and public health strategies, she is anticipated to see an increase in academic citations, particularly as global attention toward cervical cancer elimination and HPV vaccination gains momentum.

LEGACY AND FUTURE CONTRIBUTIONS

Lili Zheng is on a promising path to becoming a leading voice in HPV and cervical cancer research within China and beyond. Her future contributions are likely to focus on:

• Enhancing community-based interventions for HPV prevention.

• Promoting evidence-based public health strategies.

• Bridging clinical research with policy development.

• Advancing scientific literacy through academic and library services.

Her legacy will be defined by her commitment to health education, disease prevention, and translational research, ensuring that scientific advancements reach the communities most in need.

RECOGNITION AND PROFESSIONAL IDENTITY

• Name: Lili Zheng

• Email: Lily20060306@126.com

• Institution: Liaocheng People’s Hospital

• Country: China

• Department: Central Library

• Highest Degree: Master

• Research Role: Researcher

• Research Fields:

  1. Epidemiological study of infectious diseases

  2. Research on HPV infectious diseases

  3. Diagnosis and treatment of cervical cancer

  4. Public health and preventive medicine

  5. Microbiology and Human Health

NOTABLE PUBLICATIONS

"Human papillomavirus prevalence and genotype distribution in Liaocheng men between 2016 and 2022" 

• Authors: L., Zheng, Lili , L., Zheng, Liyuan , S., Chen, Shuangfeng , J., Qi, Jieyu , K., Li, Ke
• Journal: Journal of Medical Virology
• Year: 2024

Dr. Mariola Krzyścin | Turner Syndrome | Best Researcher Award

Pomeranian Medical University in Szczecin | Poland

Author Profile

Scopus

Orcid ID

MARIOLA KRZYŚCIN, MD, PhD: A DEDICATED EXPERT IN GYNECOLOGY AND ENDOCRINOLOGY

EARLY ACADEMIC PURSUITS

Dr. Mariola Krzyścin began her medical journey at the Medical University of Warsaw, graduating in 2006 with a degree in medicine. During her studies, she also participated in an international exchange at the University of Vienna (2002–2003) under the Socrates–Erasmus Program. Driven by an early interest in maternal and newborn health, she pursued doctoral studies at K. Marcinkowski Medical University in Poznań (2008–2013), where she defended her thesis on the impact of active and passive smoking on newborns.

Her dedication to academic excellence was evident through her specialization education in obstetrics and gynecology (2009–2015) and later in endocrinology (2020–2023). She further enriched her medical knowledge with postgraduate studies in Healthcare Management at the Poznań University of Economics and Business in 2014.

PROFESSIONAL ENDEAVORS

Dr. Krzyścin's clinical journey has been diverse and international. After completing her internship in Polish hospitals, she worked at:

• Westpfalz-Klinikum GmbH, Kaiserslautern, Germany (2016–2019)

• Clinic Frankfurt Oder, Frankfurt (Oder), Germany (2020–2024)

• Pomeranian Medical University, Szczecin (2020–present)

Earlier, she served in multiple Polish institutions, including the Medical University of Poznań, Hospital in Oborniki, and SP ZOZ in Środa Wielkopolska.

She also contributed to medical education, teaching both Polish and English-speaking students in obstetrics and gynecology between 2008 and 2016.

CONTRIBUTIONS AND RESEARCH FOCUS ON TURNER SYNDROME

Dr. Krzyścin’s clinical and academic interests center around:

• Pediatric and Adolescent Gynecology

• Gynecological Endocrinology and Andrology

• Prenatal and Ultrasound Diagnostics

• Fetal Medicine and Neonatology

Her doctoral research and clinical practice reflect a strong commitment to maternal-fetal health, reproductive endocrinology, and women’s health across all life stages.

IMPACT AND INFLUENCE

Dr. Krzyścin is widely recognized for her ability to bridge clinical expertise with education and research. Her dual specializations and international experience have made her a sought-after clinician in both Poland and Germany. She contributes to advancing pediatric gynecology and endocrinology through lectures, diagnostic excellence, and continuous training.

ACADEMIC CITES

Although specific citation metrics are not listed, Dr. Krzyścin’s doctoral work and clinical engagements have influenced practices in pediatric gynecology and obstetric ultrasound. Her work is aligned with international standards, holding certifications from the Fetal Medicine Foundation, Polish Gynecological Society, and Arbeitsgemeinschaft für Kinder und Jugendgynäkologie.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Mariola Krzyścin’s legacy is marked by a harmonious blend of clinical practice, teaching, and research. Her continued efforts in pediatric and gynecological endocrinology promise to influence the next generation of clinicians. As a certified expert in fetal medicine and diagnostic ultrasound, she is poised to contribute further to early detection, preventive medicine, and patient education.

She is expected to expand her research and clinical contributions, particularly in hormonal health, adolescent gynecology, and international medical cooperation.

ADDITIONAL HIGHLIGHTS

• Certified in Good Clinical Practice (2014, 2018)

• Active participant in continuous medical training and conferences

• Holds multiple national and international certifications in prenatal and gynecological diagnostics

• Multilingual medical educator and practitioner with international clinical exposure

NOTABLE PUBLICATIONS

"Might Thyroid Function in Patients with Turner Syndrome Have a Significant Impact on Their Muscle Strength?" 

• Authors: M., Krzyścin, Mariola , E., Sowińska-Przepiera, Elzbieta , Z., Bumbuliene, Zana , A., Syrenicz, A.
• Journal: International Journal of Molecular
• Year: 2025

"The Role of Glucose, Insulin and Body Fat in Assessment of Bone Mineral Density and Trabecular Bone Score in Women with Functional Hypothalamic Amenorrhea" 

• Authors: E., Sowińska-Przepiera, Elzbieta , M., Krzyścin, Mariola , I., Syrenicz, Igor , Z., Bumbuliene, Zana , A., Syrenicz, A.
• Journal: Journal of Clinical Medicine
• Year: 2024

"Visual Impairment in Women with Turner Syndrome—A 49-Year Literature" 

• Authors: E., Soszka-Przepiera, Ewelina , M., Krzyścin, Mariola , M.M., Modrzejewska, Monika M

Dr. Marija Jelusic | Genetic Variation | Best Researcher Award

University of Zagreb School of Medicine | Croatia

Author Profile

Scopus

Orcid ID

Google Scholar

MARIJA JELUSIC, MD, MSc, PhD: A LEADING LIGHT IN PEDIATRIC RHEUMATOLOGY AND IMMUNOLOGY

EARLY ACADEMIC PURSUITS

Marija Jelusic began her medical journey with rigorous training in pediatrics, ultimately earning her MD, MSc, and PhD from the University of Zagreb, School of Medicine in Croatia. Her commitment to specialized fields such as pediatric rheumatology and clinical immunology was evident early on, forming the foundation for a career devoted to clinical excellence and scientific advancement.

PROFESSIONAL ENDEAVORS

Professor Jelusic currently serves as Full Professor of Paediatrics at the University of Zagreb and Head of the Department of Paediatric Rheumatology, Immunology and Allergology at the University Hospital Centre (UHC) Zagreb. She is also the Founder and Head of the Referral Centre for Paediatric and Adolescent Rheumatology, a recognized body under the Ministry of Health of the Republic of Croatia and a full member of the European Reference Networks – ERN-RITA.

Her leadership extends internationally through her active roles in organizations like:

• PReS (Pediatric Rheumatology European Society): Council Member, Chair of the Training and Education Committee (since 2023), Chair of the Vasculitis Working Party (since 2017), and former Secretary (2013–2017)

• EULAR (European Alliance of Associations for Rheumatology): Member of the Paediatric Committee (since 2023) and Education Committee (starting in 2025)

• PRINTO (Pediatric Rheumatology International Trials Organization): National Coordinator (since 2017)

• Croatian Pediatric Society: Council Member (since 2022)

Her previous administrative responsibilities include Secretary of the Macrophage Activation Syndrome Working Party of PReS (2014–2018) and National Coordinator for the EULAR Standing Committee for Paediatric Rheumatology (2013–2016).

CONTRIBUTIONS AND RESEARCH FOCUS ON GENETIC VARIATION

Dr. Jelusic’s research centers around pediatric rheumatology, with a significant focus on vasculitis, particularly IgA vasculitis, and personalized immunology. Her scientific pursuits delve into genetic and cellular analyses of autoimmune and autoinflammatory diseases, bridging clinical medicine and cutting-edge molecular research.

As both principal investigator and co-investigator, she has participated in numerous national and international research initiatives. Her ability to integrate clinical insight with research methodology has earned her wide recognition.

IMPACT AND INFLUENCE

Professor Jelusic is a highly sought-after speaker, having delivered over 200 invited lectures at national and international scientific meetings. Her influence resonates in medical education, research collaborations, and clinical standards within pediatric rheumatology across Europe and beyond.

She has supervised 10 PhD theses and 29 diploma theses, actively nurturing the next generation of clinical scientists and pediatric specialists. Her academic leadership ensures sustainability and growth in pediatric immunology and rheumatology.

ACADEMIC CITES

Her prolific publication record includes over 150 peer-reviewed clinical research papers, a testament to her persistent contributions to the field. Additionally, she has been awarded 18 funded research grants, including 7 as principal investigator, which demonstrate both trust and respect from the scientific funding community.

LEGACY AND FUTURE CONTRIBUTIONS

With prestigious awards from both the European and Croatian Pediatric Societies, Professor Jelusic has already cemented a formidable legacy. Her dedication to collaborative international work, innovation in pediatric immune disorders, and excellence in mentorship will continue to shape the discipline for decades to come. As she steps into roles with EULAR’s Education Committee in 2025 and continues to lead initiatives within PReS and ERN-RITA, the global pediatric community can anticipate further innovations in personalized medicine, genomic diagnostics, and evidence-based treatments for autoimmune diseases in children.

NOTABLE PUBLICATIONS

"Diagnostic approach to a child with fever of unknown origin" 

• Authors: M., Šestan, Mario , M., Frković, Marijan , N., Kifer, Nastasia , M., Jelušić, Marija
• Journal: Paediatria Croatica
• Year: 2025

"Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project" 

• Authors: F., Baldo, Francesco , R.G.A., Erkens, Remco G.A. , M., Mizuta, Mao , S.J., Vastert, Sebastiaan J. , F., Minoia, Francesca
• Journal: Rheumatology
• Year: 2025

"Novelties in the diagnosis and treatment of the most common systemic vasculitides in childhood" 

• Authors: M., Jelušić, Marija , M., Šestan, Mario , M., Frković, Marijan
• Journal: Paediatria Croatica
• Year: 2025

"Comparison of EULAR/PRINTO/PReS Ankara 2008 and 2022 ACR/EULAR classification criteria for granulomatosis with polyangiitis in children" 

• Authors: Ü., Kaya-Akça, Ümmüşen , E.D., Batu, Ezgi Deniz , M., Jelušić, Marija , P.A., Merkel, Peter A. , S., Ozen, Seza
• Journal: Rheumatology
• Year: 2024

"Highlights from the breakout session: vasculitis in paediatric rheumatology" 

• Authors: Y., Bayindir, Yagmur , M., Jelušić, Marija , S., Ozen, Seza
• Journal: Rheumatology
• Year: 2025

Prof. Dr. Lingyu Li | Paraganglioma | Best Researcher Award

The First Hospital of Jilin University | China

Author Profile

Scopus

LI LINGYU: A LEADER IN TUMOR IMMUNOLOGY AND TRANSLATIONAL MEDICINE

EARLY ACADEMIC PURSUITS

Born on September 30, 1987, Dr. Li Lingyu demonstrated an early passion for the biomedical sciences. She pursued rigorous academic training in medicine, eventually earning her Doctor of Medicine degree. Her early exposure to clinical oncology and translational research inspired her to delve into tumor biology, neuroendocrine tumors, and immunotherapy—fields in which she would later emerge as a national expert.

PROFESSIONAL ENDEAVORS

Currently serving as Deputy Chief Physician and Associate Professor at the Cancer Center, The First Hospital of Jilin University, Dr. Li Lingyu stands at the forefront of cancer treatment and translational research in China.

Her professional footprint extends well beyond clinical care. She holds pivotal roles across several major academic and volunteer organizations:

• Deputy Chairperson, New Seedling Committee, Tumor Nutrition Branch, Chinese Anti-Cancer Association (CACS)

• Member, Specialized Committee for Neuroendocrine Tumors, CACS

• Young Member, Tumor Markers Committee, CACS

• Member, Jilin Youth Federation

• Secretary-General, Youth Volunteer Committee, Jilin Bethune Volunteer Association

She is also a prominent voice in academic publishing:

• Invited Reviewer, Chinese Medical Journal (English Edition)

• Editor-in-Chief, Frontiers in Cell and Developmental Biology

• Editor-in-Chief, Frontiers in Oncology

CONTRIBUTIONS AND RESEARCH FOCUS ON PARAGANGLIOMA

Dr. Li Lingyu has built a research portfolio that focuses on the molecular and immunological mechanisms of small cell lung cancer (SCLC), glioblastoma, and tumor immune microenvironments. Her projects are strategically aimed at unraveling resistance to NK cell therapy and immunotherapy, with a strong emphasis on:

• Endoplasmic reticulum homeostasis

• Mitochondrial-ER calcium signaling

• Circular RNAs and encoded peptides

• Tumor immune evasion mechanisms

She is the Principal Investigator of multiple high-impact grants, notably:

1. National Natural Science Foundation of China (2025–2028) – $450,000 for work on CD97–SERCA2 complexes in SCLC immunotherapy resistance.

2. Interdisciplinary Youth Innovation Team of Jilin University – CNY 1 million for tumor immunotherapy innovations.

3. Tumor Immunity Special Zone Project – CNY 3 million for immune tolerance mechanisms in tumor microenvironments.

4. Multiple NSFC-funded projects on circular RNA, chromosomal rearrangements, and exosome research.

IMPACT AND INFLUENCE

Dr. Li Lingyu’s work bridges fundamental biology and clinical application. Her findings are influential in:

• Designing precision therapy protocols

• Advancing immune cell-based treatments

• Improving diagnostic strategies through biomarker development

As a recognized leader among young oncologists and translational researchers in China, she also contributes significantly to scientific mentorship and community health awareness.

Her leadership in national and provincial medical associations also reflects her policy-level influence in shaping the direction of cancer research in China.

ACADEMIC CITES

While exact citation metrics are not listed, the volume and caliber of funded projects and her editorial leadership in two leading journals suggest a robust academic citation profile. Her research articles are likely widely cited in the fields of:

• Tumor immunology

• Cancer biomarker discovery

• Small cell lung cancer mechanisms

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Li Lingyu's legacy is being built on a foundation of scientific innovation, clinical excellence, and academic leadership. As she leads multi-disciplinary teams, mentors future medical scientists, and publishes transformative research, her trajectory suggests she will:

• Shape the future of immunotherapeutic strategies in oncology

• Lead cross-disciplinary collaborations on cancer resistance mechanisms

• Develop next-generation diagnostic and therapeutic platforms

Her continuing roles in policy, publication, and mentorship will ensure that her impact extends well beyond the laboratory and clinic.

HIGHLIGHTS OF ACHIEVEMENT

• Deputy Chief Physician, Associate Professor

• Principal Investigator on 10+ major research projects

• Editorial leadership in two major scientific journals

• Recognized young academic leader in tumor biology and immunotherapy

• Influential member of multiple national cancer research associations

NOTABLE PUBLICATIONS

"Prognostic significance of Ki-67 in assessing the risk of progression, relapse or metastasis in pheochromocytomas and paragangliomas" 

• Authors: Z., Luo, Zilan , X., Yan, Xu , Y., Liu, Yang , Y., Ren, Yuan , L., Li, Lingyu
• Journal: Annals of Medicine
• Year: 2025

"Full text Full text menu is disabled 0 Citations Article • Open access CircARAP2 controls sMICA-induced NK cell desensitization by erasing CTCF/PRC2-induced suppression in early endosome marker" 

• Authors: RAB5A F., Guo, Feifei , N., Du, Nawen , X., Wen, Xue , J., Hu, Jifan , J., Cui, Jiuwei
• Journal: Cellular and Molecular Life Sciences
• Year: 2024

"Development and validation of a nomogram prognostic model for small cell lung cancer optimized by age and metastatic pattern " 

• Authors: H., Guo, Hanfei , H., Tuerxun, Halahati , W., Li, Wenqian , L., Li, Lingyu , J., Cui, Jiuwei
• Journal: Precision Nutrition
• Year: 2023

Mr. Zhongping Chen | Ophthalmology | Best Researcher Award

Aier Eye Hospital Group Co., Ltd. Changsha Aier Eye Hospital | China

Author Profile

Scopus

‍ ZHONGPING CHEN: A VISIONARY IN OPHTHALMOLOGICAL RESEARCH AND CLINICAL CARE

EARLY ACADEMIC PURSUITS

Zhongping Chen embarked on his journey in the medical sciences with a Bachelor’s degree from Hengyang Medical College, majoring in Ophthalmology, Ear, Nose, and Throat (1986–1991). His dedication to eye health led him to pursue postgraduate studies at Central South University, where he obtained a Master's degree in Ophthalmology (2001–2003) and further advanced his expertise with a Ph.D. in the same discipline (2003–2006). These foundational academic pursuits established the basis for his later groundbreaking clinical and research contributions in ophthalmology, especially in retinal diseases and diabetic retinopathy.

PROFESSIONAL ENDEAVORS

Zhongping Chen's professional journey began as a Physician at Hengyang First People's Hospital (1991–1997), where he laid the groundwork for his clinical excellence. He was later promoted to Attending Physician in the Department of Ophthalmology (1997–2001), solidifying his reputation for patient-centered care. His academic credentials and clinical experience led him to serve as Associate Professor at the First Affiliated Hospital of the University of South China (2006–2011). By 2011, he transitioned to a more specialized role as Chief Physician at Changsha Aier Eye Hospital under the Aier Eye Hospital Group. Since 2013, he has continued his service as Chief Physician at Aier Eye Hospital, Central South University, where he combines clinical practice with scientific research and mentorship.

CONTRIBUTIONS AND RESEARCH FOCUS ON OPHTHALMOLOGY

Zhongping Chen has been at the forefront of ophthalmological research, particularly in retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. His work emphasizes the molecular mechanisms underpinning these diseases, focusing on pathways such as SP1-Nrf2-ARE and the role of matrix metalloproteinases. His research interests reflect a translational approach—bridging laboratory findings with clinical applications to improve patient outcomes.

Notable research projects include:

• Regulation of autophagy via the SP1-Nrf2-ARE pathway for disease prevention (2021JJ30046).

• Investigating matrix metalloproteinases in retinal vein occlusion treatment (2020SKC2007).

• Exploring Probucol’s effect on diabetic retinopathy through molecular signaling pathways (2018JJ2001, Kq1602026).

• Studying potassium ion channel regulation in Müller cells related to diabetic macular edema (81570876).

IMPACT AND INFLUENCE

Zhongping Chen's research has had a significant impact on clinical treatment strategies for retinal disorders. His insights into the predictive role of molecular markers and pathway-based therapeutic targets have influenced both clinical protocols and future research directions in China and beyond. He is recognized for merging clinical acumen with molecular science, thereby contributing to the optimization of personalized treatment strategies for patients with retinal complications.

ACADEMIC CITES

His research projects, many funded by prestigious organizations such as the National Natural Science Foundation of China and the Hunan Provincial Natural Science Foundation Committee, have resulted in peer-reviewed publications that continue to be cited in the academic community. These citations reflect both the clinical relevance and scientific robustness of his work, particularly in retinal pharmacology and diabetic retinopathy.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Zhongping Chen’s legacy lies in his integrated approach—blending clinical excellence, academic rigor, and innovative research. His work continues to shape ophthalmology practices in China, especially regarding evidence-based treatment for retinal diseases. Looking forward, he is expected to further expand his research into neuroprotective strategies and molecular imaging, contributing to earlier diagnoses and more targeted therapies.

NOTABLE PUBLICATIONS

"Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment" 

• Authors: T., Guo, Tingting , Y., Zhao, Yanying , S., Liang, Shengnan , H., Xu, Heping , Z., Chen, Zhongping
• Journal: Journal of Inflammation Research
• Year: 2025

"Intraocular complement activation is independent of systemic complement activation and is related to macular vascular remodelling in retinal vein occlusion" 

• Authors: H., Liu, Hengwei , Y., Zhou, Yufan , J., Qi, Jinyan , H., Xu, Heping , Z., Chen, Zhongping
• Journal: BMC Ophthalmology
• Year: 2024